GlassScriptPhysician profile
Kyle N Ota
NPI 1942682117
$7,504.04
in general payments reported to CMS, 2019-2025
29 companies · $2,710 in 2025
The $2,710 reported for 2025 was more than what 84% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $645 · 2022: $1,029 · 2023: $2,498 · 2024: $622 · 2025: $2,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,700 · Travel and Lodging: $2,613 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Gift: $16.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,700.41 |
| Travel and Lodging | $2,613.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Gift | $16.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,471.78 | 2022-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Medtronic, INC. | $2,433.88 | 2021-2025 | Progrip, Interstim, Transorb |
| Davol INC. | $595.98 | 2025 | Phasix Mesh |
| Tela Bio, INC. | $466.87 | 2021-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Ethicon US, LLC | $276.20 | 2021-2023 | Echelon; Endopath |
| Medical Device Business Services, INC. | $244.53 | 2021-2024 | Harmonic |
| Abbvie INC. | $156.00 | 2021-2023 | |
| Boston Scientific Corporation | $148.30 | 2023-2025 | Resolution 360 Clip |
| Cook Medical LLC | $126.84 | 2022 | |
| Biogen, INC. | $99.80 | 2022 | |
| Ucb, INC. | $61.99 | 2023 | Briviact |
| Zogenix INC. | $34.77 | 2021 | |
| Braintree Laboratories, INC. | $32.40 | 2023 | Sutab |
| Kowa Pharmaceuticals America, INC. | $30.36 | 2022 | |
| Argenx US, INC. | $29.85 | 2023 | Vyvgart |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $28.75 | 2022 | |
| Kyowa Kirin, INC. | $28.03 | 2021 | |
| Eisai INC. | $24.33 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.19 | 2022 | |
| Adamas Pharmaceuticals, INC. | $24.14 | 2021 | |
| Becton, Dickinson and Company | $21.56 | 2024 | |
| Neurocrine Biosciences, INC. | $20.89 | 2023 | Ingrezza, Ongentys |
| Csl Behring | $20.80 | 2021 | |
| Integra Lifesciences Corporation | $19.90 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Cala Health, INC. | $18.61 | 2023 | Cala Trio, Cala Kiq |
| Amneal Pharmaceuticals LLC | $17.23 | 2022 | |
| Karl Storz Endoscopy-America | $16.54 | 2021 | |
| Heron Therapeutics, INC. | $15.06 | 2022 | |
| Axonics, INC. | $14.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Ota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.